Myocardial-associated B lymphocytes and inflammatory injury
心肌相关B淋巴细胞与炎症损伤
基本信息
- 批准号:10339541
- 负责人:
- 金额:$ 47.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdoptive TransferAffectAmericanAnimalsAnti-Inflammatory AgentsAntibodiesAntibody FormationAntigen PresentationAntigen Presentation PathwayAntigensB Cell ProliferationB cell therapyB-Cell ActivationB-Cell Antigen ReceptorB-Cell DevelopmentB-LymphocytesBindingBiologyCCR5 Signaling PathwayCCR5 geneCXCL13 geneCardiacCell Adhesion MoleculesCellsCellular biologyChronicCoculture TechniquesDataDevelopmentDiseaseDisease ProgressionEndothelial CellsEndotheliumEnvironmentGoalsHeartHeart InjuriesHeart failureHistologicHistologyImmune responseIn VitroInflammationInflammatoryInflammatory ResponseInjuryInnovative TherapyKnowledgeMacacaMediatingMusMyocardialMyocardial InfarctionMyocardial IschemiaMyocardial dysfunctionMyocardial tissueMyocardiumP-selectin ligand proteinPathway interactionsPatientsPharmacologyPlayPopulationProcessProliferatingReactionReperfusion InjuryReporterReportingResearchResearch PersonnelRodentRoleScientistSeasonsSignal TransductionSpleenSplenectomyStructureSystemTechniquesTestingTherapeutic InterventionTimeLineTransgenic MiceTransplantationVisionWorkbasecell motilitycytokineexperienceheart damageheart functionhuman tissueimmunomodulatory therapiesimmunoregulationimprovedin vivoinjuredinnovationintravital microscopymyocardial injurynonhuman primateperipheral bloodpreventrational designrecruitresponsesingle cell sequencingsmall moleculesystemic inflammatory responsetargeted treatmenttherapeutic target
项目摘要
Project Summary/Abstract:
Heart failure is a debilitating disease. A growing body of evidence indicates that inflammation plays an
important role in the development and progression of this disease. However, the development of
immunomodulatory based treatments for heart failure has, so far, been mostly unsuccessful.
The PI recently described a population of circulating B cells that adheres to the myocardial endothelium
and found that B cell deficient animals have alterations in cardiac structure and function. Moreover, he found
that, in rodents, small molecule-mediated modulation of myocardial B cells improves cardiac function after heart
attacks. These findings, together with emerging evidence from other research groups, suggest that B cells might
be a powerful target for the development of immunomodulatory therapies to prevent and treat cardiac
dysfunction. However, our current understanding of myocardial B cell biology is critically lacking.
Heart damage triggers a local and systemic inflammatory response characterized by recruitment of
inflammatory cells to the injured heart and rapid changes in the spleen. Currently, it is unclear if and how B cells
are recruited into the injured myocardium. Moreover, even though B cells account for about half of all the cells
in the spleen, and splenic inflammatory changes induced by heart damage have been shown to play a critical
role in the progression of heart failure, it is unclear if B cells play a role in the splenic immune response triggered
by heart damage. In addition, it remains unknown whether B cell mediated antigen presentation (that together
with antibody production and cytokine secretion is one of the 3 prototypical functions of B cells) plays any role
within the inflammatory response triggered by cardiac injury. Finally, at an even more basic level, it is unknown
how B cells adhere to the endothelium of the uninjured heart. Here, the PI proposes to fill these gaps in
knowledge by testing the hypothesis that circulating B cells bind to the myocardial endothelium through specific
adhesion molecules and, in response to myocardial injury, enter the myocardium through a CXCL13-CCR5
dependent process, are activated and proliferate in an antigen independent manner, and recirculate between
the heart and the spleen to amplify the inflammatory reaction elicited by cardiac damage via MHC-II mediated
antigen presentation. The long-term goal of the PI is to use the knowledge gained to facilitate the development
of B cell-targeted therapies for heart failure.
The PI has been a pioneer in the study of the interaction between B cells and the heart. He is a junior
investigator, but he has mastered all the techniques needed to test this hypothesis, he is supported by several
seasoned scientists that are co-investigators or collaborators in this proposal, and works within a highly
collaborative research environment focused on excellence and innovation. He, therefore, is aptly qualified to
effectively test this innovative hypothesis and address, within the timeline of this proposal, the critical knowledge
gaps described.
项目概要/摘要:
心力衰竭是一种使人衰弱的疾病。越来越多的证据表明,炎症在
在这种疾病的发展和进展中起着重要作用。但发展
迄今为止,基于免疫调节的心力衰竭治疗大多不成功。
PI最近描述了粘附于心肌内皮的循环B细胞群
发现缺乏B细胞的动物心脏结构和功能发生改变。此外,他发现
在啮齿类动物中,小分子介导的心肌B细胞调节可改善心脏移植后的心脏功能。
攻击这些发现,以及其他研究小组的新证据表明,B细胞可能
成为开发预防和治疗心脏病的免疫调节疗法的有力目标
功能障碍然而,我们目前对心肌B细胞生物学的了解严重缺乏。
心脏损伤引发局部和全身炎症反应,其特征在于招募
炎症细胞向受损的心脏和脾脏的快速变化。目前,还不清楚B细胞是否以及如何
被招募到受伤的心肌中此外,尽管B细胞约占所有细胞的一半,
心脏损伤引起的脾脏炎性变化已被证明在
虽然B细胞在心力衰竭的进展中起重要作用,但目前尚不清楚B细胞是否在脾免疫反应中起作用
心脏受损此外,B细胞介导的抗原呈递(即共同的抗原呈递)
抗体产生和细胞因子分泌是B细胞的3种典型功能之一)起任何作用
在心脏损伤引发的炎症反应中最后,在更基本的层面上,
B细胞是如何粘附在未受损心脏的内皮上的。在这里,PI建议填补这些空白,
通过检验循环B细胞通过特异性结合心肌内皮细胞的假设,
粘附分子,并响应心肌损伤,通过CXCL 13-CCR 5进入心肌
依赖性过程,以抗原非依赖性方式被激活和增殖,并在
通过MHC-II介导的心脏和脾脏放大心脏损伤引起的炎症反应
抗原呈递PI的长期目标是利用获得的知识促进开发
B细胞靶向疗法治疗心力衰竭。
PI是研究B细胞与心脏相互作用的先驱。他是一个大三学生
虽然他是一名调查员,但他已经掌握了测试这一假设所需的所有技术,他得到了几个人的支持。
经验丰富的科学家,是共同研究者或合作者在这个建议,并在一个高度
协作研究环境注重卓越和创新。因此,他完全有资格
有效地测试这一创新假设,并在本提案的时间轴内解决关键知识
描述的差距。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Luigi Adamo其他文献
Luigi Adamo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Luigi Adamo', 18)}}的其他基金
Myocardial-associated B lymphocytes and inflammatory injury
心肌相关B淋巴细胞与炎症损伤
- 批准号:
10543825 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Phenotype, dynamics and activation of myocardial B lymphocytes in response toischemia/reperfusion injury
心肌 B 淋巴细胞响应缺血/再灌注损伤的表型、动力学和激活
- 批准号:
10261534 - 财政年份:2019
- 资助金额:
$ 47.96万 - 项目类别:
Phenotype, dynamics and activation of myocardial B lymphocytes in response toischemia/reperfusion injury
心肌 B 淋巴细胞响应缺血/再灌注损伤的表型、动力学和激活
- 批准号:
10689042 - 财政年份:2019
- 资助金额:
$ 47.96万 - 项目类别:
Phenotype, dynamics and activation of myocardial B lymphocytes in response toischemia/reperfusion injury
心肌 B 淋巴细胞响应缺血/再灌注损伤的表型、动力学和激活
- 批准号:
10463823 - 财政年份:2019
- 资助金额:
$ 47.96万 - 项目类别:
Phenotype, dynamics and activation of myocardial B lymphocytes in response toischemia/reperfusion injury
心肌 B 淋巴细胞响应缺血/再灌注损伤的表型、动力学和激活
- 批准号:
10251619 - 财政年份:2019
- 资助金额:
$ 47.96万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.96万 - 项目类别:
Research Grant